The hematology diagnostic market is estimated to be valued at US$ 780.0 million in 2023 and is rising to US$ 2.0 billion by 2033. The market is estimated to register a CAGR of 9.9% during the forecast period. Various factors influencing the market include:
| Attributes | Details |
|---|---|
| Market CAGR (2023 to 2033) | 9.9% |
| Market Valuation (2023) | US$ 780 million |
| Market Valuation (2033) | US$ 2.0 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The rising costs of hematology diagnostic and novel diagnostic procedures are limiting the market growth as people in low and middle-income countries find it difficult to receive expensive treatment, whereas lack of awareness may also restrict the market growth.
The rapidly growing blood diseases, related disorders, and infections such as blood clots, anemia, cancer, and hemophilia are driving market expansion. A report published by Bristol-Myers Squibb stated that nearly one million cases of blood cancer were recorded globally in 2020. Additionally, rising hemoglobinopathies disorder may increase the market growth during the forecast period.
The adoption of automation in hematology diagnostics to improve efficiency and standardize processes are rising market opportunity. Various diagnostic laboratories accept automation processes to collect samples, avail quick results, and recognition tests, and reduce administrative errors. These factors are estimated to increase the demand for automated hematology diagnostics during the forecast period.
Principal Consultant
According to Future Market Insights, the global hematology diagnostics market is projected at a healthy CAGR of 9.9% during the forecast period. Historically, the market registered a CAGR of 11.8% between 2017 and 2022.
The market changes as per the product adoption rates and device regulations under the macro and industrial dynamics. The key developments in the market include complete lab automation for hematology diagnostics. With the fourth wave of technology and automation around the globe, the market has been positively influenced by total laboratory automation strategies.
The market is estimated to reach US$ 2.0 billion during the forecast period. In the historical period, the market stood at a valuation of US$ 700 million from 2017 to 2022.
| Segments | Kit Type |
|---|---|
| Top Category | Blood Typing Kits |
| Historic CAGR | 11.2% |
| Forecast CAGR | 9.4% |
| Segments | Modality |
|---|---|
| Top Category | Lab-based Testing |
| Historic CAGR | 11% |
| Forecast CAGR | 9.1% |
The hospital segment holds a dominant market share and is predicted to maintain this stance during the forecast period. However, the diagnostic laboratories segment is expected to experience rapid growth over the forecast period owing to an increase in diagnostic centers. The increasing availability of advanced diagnostic instruments and devices and the demand for hospitals propel market growth.
Based on kit type, blood typing kits lead the global market by securing a CAGR of 9.4% during the forecast period. The rising demand for blood typing kits to perform blood tests easier and quicker and identify blood types. This segment contributes a huge revenue in the general healthcare routine and in discovering diseases which may drive market expansion.
The blood typing kits check various tests such as iron deficiency, allergy, vitamins, and anemia propel market opportunities. Historically, the blood typing kits captured a CAGR of 11.2% between 2017 and 2022.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Country | United States |
|---|---|
| AGR (2017 to 2022) | 11.5% |
| AGR (2023 to 2023) | 9.7% |
| Valuation (2023 to 2033) | US$ 708.6 million |
| Country | United Kingdom |
|---|---|
| AGR (2017 to 2022) | 10.5% |
| AGR (2023 to 2023) | 8.9% |
| Valuation (2023 to 2033) | US$ 84.2 million |
| Country | China |
|---|---|
| AGR (2017 to 2022) | 11.1% |
| AGR (2023 to 2023) | 9.3% |
| Valuation (2023 to 2033) | US$ 143.5 million |
| Country | Japan |
|---|---|
| AGR (2017 to 2022) | 10.0% |
| AGR (2023 to 2023) | 8.4% |
| Valuation (2023 to 2033) | US$ 117.3 million |
| Country | South Korea |
|---|---|
| AGR (2017 to 2022) | 8.6% |
| AGR (2023 to 2023) | 7.6% |
| Valuation (2023 to 2033) | US$ 69 million |
Rising Incidence of Blood Cancer to Boost Hematology Diagnostics Demand!
The USA is securing a CAGR of 9.7% with a valuation of US$ 708.6 million during the forecast period. The USA has seen a spike in the incidence of blood cancer in recent years, and it is expected to increase in the coming years. Due to high technological proliferation, the USA hematology diagnostics market is expected to provide lucrative opportunities.
The presence of developed healthcare infrastructure and high research and development activity is predicted to flourish the USA market during the forecast period. Historically, the USA market captured a CAGR of 11.5% between 2017 and 2022.
South Korea registers a CAGR of 7.6% with a valuation of US$ 69 million during the forecast period. Focus on healthcare has bolstered in recent years in South Korea, creating many opportunities for healthcare diagnostic providers. The nation is also experiencing a surge in blood disorders and incidences of blood cancer. These factors are propelling the South Korean market during the forecast period. Historically, the market secured a CAGR of 8.6% between 2017 and 2022.
The United Kingdom's hematology diagnostics market is anticipated to hold a CAGR of 8.9%, with a valuation of US$ 84.2 million during the forecast period. The rising prevalence of blood cancer and the presence of key hematology diagnostics companies are expected to be key factors propelling the market growth.
The rising research & development and government initiatives to boost awareness for hematology diagnostics are driving the United Kingdom market. The increasing prevalence of blood disorders, healthcare, and rising instances of genetic blood disorders are expected to propel the United Kingdom market.
Rising investments in healthcare infrastructure and new market entrance are anticipated to promote the market potential in this region. Historically, the United Kingdom market secured a CAGR of 10.5% between 2017 and 2022.
The China hematology diagnostics market is anticipated to hold a CAGR of 9.3% with a valuation of US$ 143.5 million during the forecast period. Increasing healthcare infrastructure, urbanization, and improvement in diagnostic therapy products are driving the China market.
Rising government regulations and increasing initiatives to generate awareness are anticipated to boost market growth during the forecast period. Historically, China secured a CAGR of 11.1% between 2017 and 2022.
Hematology diagnostic providers are investing in the research & development of novel diagnostic solutions to enhance their market presence and boost revenue. Hematology diagnostic companies also focus on establishing new centers to deploy novel diagnostic solutions.
Healthcare manufacturers are developing various automation devices to reduce the workload and provide efficient results. Key players are conducting extensive research on the market and carrying out several marketing strategies to upsurge the market. Moreover, market players are involved in innovating new products and expanding distribution networks in the coming years.
Recent Development in the Market
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data | 2017 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Countries Covered | United States, Canada, Germany, United Kingdom, France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Northern Africa, and South Africa, Türkiye |
| Key Segments Covered | Kit Type, Modality, Distribution Channel, Region |
| Key Companies Profiled | Meyland Smith A/S; Abbot Laboratories; Bio-Rad Laboratories; Sysmex Corporation; Mindray Medical International Limited; Siemens Healthlineers; F. Hoffman-La Roche Ltd.; HORIBA Ltd.; HemoCue AB; Danaher (Beckman Coulter Inc.); Nihon Kohden Corporation; EKF Diagnostics; Ortho Clinical Diagnostics; Drew Scientific |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global hematology diagnostics market might create a revenue of around US$ 780 million in 2023.
In the United States the net worth of the total hematology diagnostics adopted by 2033 could be US$ 708.6 million.
China is the leading market and the regional demand is expected to grow at 9.3% CAGR until 2033.
The blood typing kits segment dominated and is forecasted to register 9.4% CAGR through 2033.
Between 2017 and 2022, the global demand for hematology diagnostics services surged at 11.8%.
1. Executive Summary | Hematology Diagnostics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyers
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ million) & Volume (Units) Analysis, 2017 to 2022
4.2. Current and Future Market Size Value (US$ million) & Volume (Units) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Kit Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Kit Type, 2017 to 2022
5.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Kit Type, 2023 to 2033
5.3.1. Anemia and Iron Test Kits
5.3.2. Folic Acid Testing Kits
5.3.3. Sickle Cell Screening Kits
5.3.4. PT/INR Testing Kits
5.3.5. D-dimer Testing Kits
5.3.6. Blood Typing Kits
5.3.7. Leukemia Testing Kits
5.3.8. Sepsis Testing Kits
5.3.9. Antibiotic Resistance Panels
5.3.10. Bacterial & Fungal Panels
5.4. Y-o-Y Growth Trend Analysis By Kit Type, 2017 to 2022
5.5. Absolute $ Opportunity Analysis By Kit Type, 2023 to 2033
6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Modality
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Modality, 2017 to 2022
6.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Modality, 2023 to 2033
6.3.1. Point of Care
6.3.2. Lab-based Testing
6.4. Y-o-Y Growth Trend Analysis By Modality, 2017 to 2022
6.5. Absolute $ Opportunity Analysis By Modality, 2023 to 2033
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Distribution Channel, 2017 to 2022
7.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospitals
7.3.2. Diagnostic Laboratories
7.3.3. Cancer Research Institutes
7.3.4. Retail Pharmacies
7.3.5. Drug Store
7.3.6. Online Sales Channels
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Region, 2017 to 2022
8.3. Current Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia & Pacific
8.3.6. Middle East and Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
9.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. United States of America
9.2.1.2. Canada
9.2.2. By Kit Type
9.2.3. By Modality
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Kit Type
9.3.3. By Modality
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
10.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Kit Type
10.2.3. By Modality
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Kit Type
10.3.3. By Modality
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
11.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. Spain
11.2.1.4. France
11.2.1.5. Italy
11.2.1.6. Rest Of Europe
11.2.2. By Kit Type
11.2.3. By Modality
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Kit Type
11.3.3. By Modality
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
12.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Kit Type
12.2.3. By Modality
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Kit Type
12.3.3. By Modality
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. South Asia & Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
13.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Malaysia
13.2.1.2. Singapore
13.2.1.3. Philipinnes
13.2.1.4. Indonesia
13.2.1.5. Australia
13.2.1.6. New Zealand
13.2.1.7. Rest of South Asia & Pacific
13.2.2. By Kit Type
13.2.3. By Modality
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Kit Type
13.3.3. By Modality
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
14.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. Turkey
14.2.1.3. South Africa
14.2.1.4. Rest of MEA
14.2.2. By Kit Type
14.2.3. By Modality
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Kit Type
14.3.3. By Modality
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. United States of America
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Kit Type
15.1.2.2. By Modality
15.1.2.3. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Kit Type
15.2.2.2. By Modality
15.2.2.3. By Distribution Channel
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Kit Type
15.3.2.2. By Modality
15.3.2.3. By Distribution Channel
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Kit Type
15.4.2.2. By Modality
15.4.2.3. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Kit Type
15.5.2.2. By Modality
15.5.2.3. By Distribution Channel
15.6. United Kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Kit Type
15.6.2.2. By Modality
15.6.2.3. By Distribution Channel
15.7. Spain
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Kit Type
15.7.2.2. By Modality
15.7.2.3. By Distribution Channel
15.8. France
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Kit Type
15.8.2.2. By Modality
15.8.2.3. By Distribution Channel
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Kit Type
15.9.2.2. By Modality
15.9.2.3. By Distribution Channel
15.10. China
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Kit Type
15.10.2.2. By Modality
15.10.2.3. By Distribution Channel
15.11. Japan
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Kit Type
15.11.2.2. By Modality
15.11.2.3. By Distribution Channel
15.12. South Korea
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Kit Type
15.12.2.2. By Modality
15.12.2.3. By Distribution Channel
15.13. Malaysia
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Kit Type
15.13.2.2. By Modality
15.13.2.3. By Distribution Channel
15.14. Singapore
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Kit Type
15.14.2.2. By Modality
15.14.2.3. By Distribution Channel
15.15. Philipinnes
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Kit Type
15.15.2.2. By Modality
15.15.2.3. By Distribution Channel
15.16. Indonesia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Kit Type
15.16.2.2. By Modality
15.16.2.3. By Distribution Channel
15.17. Australia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Kit Type
15.17.2.2. By Modality
15.17.2.3. By Distribution Channel
15.18. New Zealand
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Kit Type
15.18.2.2. By Modality
15.18.2.3. By Distribution Channel
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Kit Type
15.19.2.2. By Modality
15.19.2.3. By Distribution Channel
15.20. Turkey
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Kit Type
15.20.2.2. By Modality
15.20.2.3. By Distribution Channel
15.21. South Africa
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Kit Type
15.21.2.2. By Modality
15.21.2.3. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Kit Type
16.3.3. By Modality
16.3.4. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Meyland Smith A/S
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Abbot Laboratories
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Bio-Rad Laboratories
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Sysmex Corporation
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Mindray Medical International Limited
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Siemens Healthlineers
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. F. Hoffman-La Roche Ltd.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. HORIBA Ltd.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. HemoCue AB
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. Danaher (Beckman Coulter Inc.)
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
17.1.11. Nihon Kohden Corporation
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.11.5.2. Product Strategy
17.1.11.5.3. Channel Strategy
17.1.12. EKF Diagnostics
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.12.5.2. Product Strategy
17.1.12.5.3. Channel Strategy
17.1.13. Ortho Clinical Diagnostics
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.13.5.2. Product Strategy
17.1.13.5.3. Channel Strategy
17.1.14. Drew Scientific
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
17.1.14.5.2. Product Strategy
17.1.14.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Hematology Diagnostics Market
